WO1990003959A1 - Milieu solide et procede de stockage d'adn - Google Patents

Milieu solide et procede de stockage d'adn Download PDF

Info

Publication number
WO1990003959A1
WO1990003959A1 PCT/AU1989/000430 AU8900430W WO9003959A1 WO 1990003959 A1 WO1990003959 A1 WO 1990003959A1 AU 8900430 W AU8900430 W AU 8900430W WO 9003959 A1 WO9003959 A1 WO 9003959A1
Authority
WO
WIPO (PCT)
Prior art keywords
dna
solid medium
solid
composition
blood
Prior art date
Application number
PCT/AU1989/000430
Other languages
English (en)
Inventor
Leigh Alexander Burgoyne
Original Assignee
The Flinders University Of South Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Flinders University Of South Australia filed Critical The Flinders University Of South Australia
Publication of WO1990003959A1 publication Critical patent/WO1990003959A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6879—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for sex determination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Definitions

  • This invention relates to a solid medium for use in the storage of DNA, particularly DNA in blood samples, and to methods which comprise the use of this solid medium.
  • the invention relates to a method for storage and transport of DNA on the solid medium, as well as to methods which involve either (a) the recovery of the DNA from the solid medium or (b) the use of the DNA in situ on the solid medium (for example, DNA sequence .amplification by the polymerase chain reaction) .
  • blood DNA The DNA in blood samples (hereinafter referred to as "blood DNA”) is used for the purposes of diagnosis of genetic diseases, diagnosis and monitoring of blood-borne parasitic diseases such as malaria, the determination of paternity, and the monitoring of other unusual cell populations in the blood as can occur in some neoplasias.
  • blood DNA is used to cover all sources of DNA commonly found in blood, and thus includes the DNA of the human patient from whom the blood sample was obtained, as well as the DNA in any other organisms circulating within his/her blood.
  • a solid medium for storage of DNA including blood DNA, which comprises a solid matrix having a compound or composition which protects against degradation of DNA incorporated into or absorbed on the matrix.
  • the solid matrix comprises a solid support, for example, an absorbent cellulose-based paper (such as filter paper) or a mi ⁇ romesh of synthetic plastics material, with the DNA-protecting compound or composition absorbed onto the solid support.
  • the solid matrix may include a suitable binder material so that the matrix is in the form of a compressed tablet or pellet, with the DNA-protecting compound or composition incorporated into or absorbed onto the tablet or pellet.
  • the present invention also provides a method for the storage of DNA, including blood DNA, which comprises applying the DNA to a solid medium which comprises a solid matrix having a compound or composition which protects against degradation of DNA incorporated into or adsorbed on the matrix.
  • the DNA-protecting compound or composition comprises uric acid, together with a weak base to convert the uric acid to a urate salt and to provide an alkaline pH between 8.0 and 9.5.
  • a solid medium for storage of blood DNA which comprises a solid matrix having incorporated therein or absorbed thereon a composition comprising a weak base, a chelating agent and an anioni ⁇ surfactant or detergent, and optionally uric acid or a urate salt.
  • the composition imposes an alkaline pH, such as a pH of between 8.0 and 9.5, on blood that is added to the matrix.
  • an alkaline pH such as a pH of between 8.0 and 9.5
  • a further aspect of the present invention is the long term storage of DNA on the solid medium of this invention, by impregnating the solid medium or encasing the solid medium in a protective material, for example a plastics material such as polystyrene, which can be subsequently removed when access to the stored DNA is required.
  • a protective material for example a plastics material such as polystyrene
  • the blood sample is applied as a blood spot to the solid medium of this aspect of the invention, where the components more particularly the surfactant will denature proteins and the majority of any pathogenic organisms in the sample.
  • the blood DNA will be protected from degradation factors and processes of the type described above so that the relatively stable, and denatured, dried blood sample can then be transported to a diagnostic laboratory . There, the DNA can be extracted or the DNA used in situ on the solid medium.
  • the composition used in this aspect of this invention comprises the following: (i) a monovalent weak base (such as "Tris", tris- hydroxymethyl methane, either as the free base or as the carbonate) ;
  • a monovalent weak base such as "Tris", tris- hydroxymethyl methane, either as the free base or as the carbonate
  • a chelating agent such as EDTA, ethylene diamine tetracetic acid
  • an anionic detergent such as SDS, sodium dodecyl sulphate
  • uric acid or a urate salt optionally (iv) uric acid or a urate salt.
  • a particularly preferred solid medium according to this aspect of the invention comprises an absorbent cellulose-based paper such as filter paper having a minimal loading, per sq.cm. of paper, as follows:
  • uric acid or a urate salt in accordance with this invention has been found to be particularly important for the long term storage of DNA as this component performs a number of functions. Firstly, it is converted into allantoin in acting as a "free-radical" trap that preferentially accepts free radicals, that would otherwise damage the base guanine in the DNA, (e.g. 2 ' 3 ) . Such free radicals are generated by the spontaneous oxidation of thio groups in the denatured serum protein, and may also be generated by the large amount of iron in blood*.
  • the uric acid also acts as a component of the buffering system in that it is a weak acid. It also acts as an erodible surface in that it is sparingly soluble so that DNA-containing material dried onto its crystals will be released as the urate beneath them erodes.
  • the composition may include a base, optionally a monovalent weak base, to cause an alkaline pH between 8.0 and 9.5 to be imposed upon the blood that is placed upon the matrix. This is to ensure the proper action of the chelating agent in binding divalent metals. It is also to prevent the action of acid nucleases that are not so dependent on divalent metals.
  • the base may be a weak organic base, such as Tris.
  • an inorganic base such as an alkali metal carbonate or bicarbonate, for example sodium, lithium or potassium carbonate or bicarbonate, may be used.
  • the chelating agent is preferably a strong chelating agent such as EDTA, however a wide range of suitable strong chelating agents are commercially available.
  • the function of the chelating agent is to bind the divalent metal ions, magnesium and calcium, and also to bind transition metal ions, particularly iron. Both calcium and magnesium are known to promote DNA degradation by acting as co-factors for enzymes.
  • the metal ions such as iron, that readily undergo oxidation and reduction also damage nucleic acids by the production of free radicals 4 .
  • the anionic surfactant or detergent is included in the composition of this aspect of the invention as the primary denaturing agent. Any strong anionic detergent that binds to and denatures proteins is suitable, and as well as SDS mentioned above other detergents such as sodium lauryl sarcosinate may also be used. This anionic detergent causes most pathogens to be inactivated due to the non-specific destruction of the secondary structure of their coat proteins, their internal proteins, and any membranes they may be dependent upon. There are exceptions, since the anionic detergent does not inactivate the most resistant bacterial spores, nor does it inactivate some extremely stable enteric virions. However, these exceptions are agents that are already likely to be transferred by ordinary contact and there is currently no great concern that these agents constitute a risk from blood.
  • the treated paper was soaked with drops of blood from various primates.
  • the blood-stained paper was dried, sent through the ordinary mail so that it spent at least three days in the mail, and then had the DNA extracted from it using standard procedures involving detergent-aided proteolysis and phenol extraction of the paper.
  • the resultant DNA was then tested for its quality by being digested with restriction endonucleases and the fragments analyzed by agarose gel electrophoresis.
  • the DNA fragments were found to be as high in quality as DNA produced from fresh blood. This demonstrates that the DNA can be extracted from detergent-treated papers and that the DNA is of sufficient quality for most normal purposes.
  • EXAMPLE 2 Long-term Storage of Semi-purified or Purified DNA: Storage of DNA, such as plasmids or other viral replicating forms, has been carried out using record cards made of absorbent paper previously soaked in a solution of uric acid and tris (free base) . The cards are subsequently plasticised for further protection. This procedure has been established for the long-term storage of clones from massed dot-blots when it is possible that the original material is required at some much later date, and when a great many such massed clonings are to be kept in orderly, low-volume, files. Samples have been stored successfully this way for about four years.
  • Record cards can be prepared in batches and stored until needed. Whatman No.l paper about 10cm x 15cm in size and with appropriate places marked out with an "indian ink” (i.e. colloidal carbon ink-stamp) is suitable, and any special notes on the cards can be made with an ordinary "lead” pencil (i.e. Graphite pencil) .
  • the cards are marked out in a regular pattern to assist in systematic storage and retrieval of DNA samples. Marked cards are wrapped in clean paper, then foil, and autoclaved with a dry cycle. They are then treated with a solution of 40mM uric acid and 100mm tris (free base) . The function of the urate is to protect the DNA from aging and to aid the desorption from the paper if required. These treated record cards can then be kept until required.
  • DNA to be ⁇ stored is taken up in a dilute alkaline buffer containing EDTA, e.g. TE buffer (Tris-EDTA pH 8.0).
  • TE buffer Tris-EDTA pH 8.0
  • approx 1 ml of bacterial culture containing plasmid is treated by the alkaline lysis method, with one phenol extraction and one alcohol precipitation, to get approx 50 / il of plasmid or other DNA in TE buffer.
  • a 5 / _.l aliquot of each DNA sample is used to make a spot on the urate treated record card.
  • the DNA spots are thoroughly air-dried, then the card is dipped in 5ml of 12% w/v polystyrene in acid-free chloroform. This is preferably achieved by putting the card in a fitting polyethylene baglet and then pouring the polystyrene solution into it, spreading the polystyrene solution to thoroughly coat the card and then stripping off the soiled polyethylene. The card is then allowed to dry at room temperature.
  • the cards are conveniently stored in a sealed container in a refrigerator freezer (about -15 ⁇ C) in the presence of drying agent such as silica gel and a few grains of dry sodium carbonate to remove any traces of acid vapours. 2.5 Using DNA on plasticised cards.
  • the storage container is allowed to rise to room temperature in order to minimise unnecessary wetting and drying cycles on long-term storage cards.
  • the appropriate card is abstracted, the relevant DNA spot identified and a small sample of it cut out.
  • the desorption of DNA samples, both single and double stranded, from Whatman No.l paper soaked with a solution of 40mM uric acid, and lOOmM tris (free base) was examined by using the plasmid pUC19 as a source of standard double stranded DNA and M13 as a source of single stranded DNA.
  • EXAMPLE 3 In situ Use of Stored Blood DNA in PCR.
  • Blood DNA stored on filter paper treated in accordance with the present invention can be amplified in situ by the polymerase chain reaction (PCR) technique.
  • the treated paper used in this Example was Whatman 3 mm paper treated with a solution comprising, per sq.cm of paper, 2 micromols uric acid, 8 micromols tris (free base), 0.5 micromols EDTA and 1 mg SDS.
  • the stored blood DNA was treated to remove protein, then washed to remove phenol and add suitable ions, prior to DNA amplification.
  • Phenol solution One-phase Phenol solution.
  • a suitable mixture is phenol, 50 gm containing 120 mg of 8- hydroxyquinoline that has been saturated with 10 ml of 1.0 M tris-acetate pH 8.0 and 1.0 ml 2- mercaptoethanol. After saturation by shaking at room temperature, the aq-ueous phase is thoroughly removed and discarded.
  • Solution B 75% v/v Isopropanol, 25% v/v 0.1M potassium acetate at pH 7.8.
  • Solution C 75% v/v Isopropanol, 25% v/v 0.1M potassium acetate at pH 7.8.
  • All steps are preferably carried out in a single tube made of a suitable phenol resistant material, e.g. polyethylene.
  • step (b) Removal of phenol and addition of suitable ions: the paper in its tube from step (a) above, is rapidly washed in three lots of 1 ml of solution B. Washes are at room temperature and are simple additions followed by aspiration to waste. The paper is then washed for 20 minutes at room temperature with solution C. (This is to saturate the DNA on the paper with Magnesium ions and remove the last of the phenol. ) The solution C is aspirated to waste and the paper is solvent-dried with one wash of pure isopropanol and then vacuum dried.
  • the treated DNA-paper as described above has been shown to be a suitable substrate for DNA polymerase chain reaction (PCR) amplification of DNA.
  • PCR DNA polymerase chain reaction
  • Extracted DNA DNA from 10 ml of blood obtained from a male volunteer was extracted by standard protocols. ,
  • Treated DNA Filter Paper Blood specimens from the same volunteer were applied directly to treated filter paper with subsecjuent treatment as described above. The paper was cut into about lmm 2 pieces for use in PCR reactions.
  • Target No. 1 Region of exon 2 of the n-Ras proto-oncogene on chromosome 1.
  • the primers used are:
  • R2 5' CTC TAT GGT GGG ATC ATA TTC A 3'.
  • the amplified DNA fragment obtained with these primers is llObp in size.
  • Target No.2 A male specific Y chromosome repeat sequence.
  • the primers are:
  • the amplified DNA fragment obtained with these primers is 124 bp in size.
  • Target No.3 A male specific Y chromosome repeat sequence.
  • the primers used are:
  • 004 5' GAA TGT ATT AGA ATG TAA TGA ACT TTA 3' and 006: 5' TTC CAT TCC ATT CCA TTC CTT TCC TTT 3'.
  • the amplified DNA fragment obtained with these primers is 250 bp in size.
  • Extracted DNA (1 ⁇ g) or about 1mm 2 fragments of treated DNA filter paper were placed into 0.5ml Eppendorf tubes and made to 25 ⁇ l in PCR reaction mixture consisting of: 67 mM Tris HC1 (pH 8.8 @ 25 ⁇ C) 16.6 mM ammonium sulfate 2 mM MgCl 2 0.01% (w/v) gelatin
  • deoxynucleotides dATP, dTTP, dCTP, dGTP 0.25 ⁇ g of each primer (for respective target) 0.25 U of Taq DNA polymerase.
  • the mixture was overlaid with 25 ⁇ l of light mineral oil and DNA amplification was performed by 30 cycles of amplification on a Perkin Elmer-Cetus "thermal cycler".
  • the first cycle consisted of:
  • Taq DNA polymerase extension 1 min. @ 75"C followed by 29 cycles as above except DNA denaturation was for 1 min @ 94"C and the extension time on the last cycle was 10 min @ 72°C before cooling of reaction mixture to 4°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Un milieu solide permettant le stockage d'ADN, y compris l'ADN sanguin, comprend une matrice solide comportant un composé ou une composition assurant une protection contre la dégradation d'ADN incorporé ou absorbé dans la matrice. On a mis au point des procédés de stockage d'ADN utilisant ce milieu solide, et permettant la récuperation d'ADN ou l'utilisation d'ADN in situ.
PCT/AU1989/000430 1988-10-05 1989-10-03 Milieu solide et procede de stockage d'adn WO1990003959A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPJ0775 1988-10-05
AUPJ077588 1988-10-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/159,104 Continuation US5496562A (en) 1988-10-05 1993-11-30 Solid medium and method for DNA storage

Publications (1)

Publication Number Publication Date
WO1990003959A1 true WO1990003959A1 (fr) 1990-04-19

Family

ID=3773417

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1989/000430 WO1990003959A1 (fr) 1988-10-05 1989-10-03 Milieu solide et procede de stockage d'adn

Country Status (2)

Country Link
CA (1) CA2000192A1 (fr)
WO (1) WO1990003959A1 (fr)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039813A1 (fr) * 1995-06-07 1996-12-19 Flinders Technologies Pty. Ltd. Support solide sec pour le stockage et l'analyse d'un materiau genetique
EP0784796A1 (fr) * 1994-10-07 1997-07-23 Flinders Technologies Pty. Ltd. Appareil et procede de stockage, purification ou mise en reaction et traitement d'un biopolymere
WO1997042344A1 (fr) * 1996-05-03 1997-11-13 Institut Für Medizinische Molekulardiagnostik Gbrmbh Procede pour l'analyse genetique du sang et moyen pour sa mise en oeuvre
FR2755440A1 (fr) * 1996-11-07 1998-05-07 Tuffet Sophie Procede de conservation de longue duree de molecules d'adn et conditionnement pour sa mise en oeuvre
US5756126A (en) * 1991-05-29 1998-05-26 Flinders Technologies Pty. Ltd. Dry solid medium for storage and analysis of genetic material
US5807527A (en) * 1991-05-29 1998-09-15 Flinders Technologies Pty. Ltd. Solid medium and method for DNA storage
WO1999038962A2 (fr) * 1998-02-02 1999-08-05 Gentra Systems, Inc. Compositions et procedes d'utilisation d'une matrice lytique pour isoler un adn
US5972386A (en) * 1995-12-19 1999-10-26 Flinders Technologies Pty, Ltd. Dry solid medium for storage and analysis of genetic material
WO1999057264A1 (fr) * 1998-05-06 1999-11-11 Sophie Tuffet Procede de conservation de longue duree de molecules d'adn et conditionnement pour sa mise en oeuvre
US5985327A (en) * 1988-10-05 1999-11-16 Flinders Technologies Pty. Ltd. Solid medium and method for DNA storage
DE19957861A1 (de) * 1999-12-01 2001-06-13 Agrobiogen Gmbh Probenbehälter zur Lagerung und Identifizierung von DNA/RNA-haltigem Material
EP1173623A1 (fr) * 1999-03-11 2002-01-23 Whatman, Inc. Milieu solide et procede pour le stockage et la purification rapide d'acide nucleique
EP1177420A1 (fr) * 1999-04-14 2002-02-06 Whatman, Inc. Support revetu de fta (matiere de filtre cellulosique) utile comme outil diagnostique moleculaire
US6447804B1 (en) 1988-10-05 2002-09-10 Whatman, Plc Dry solid medium for storage and analysis of genetic material
US6627226B2 (en) 1988-10-05 2003-09-30 Whatman, Inc. Dry solid medium for storage and analysis of genetic material
EP1557475A1 (fr) * 2004-01-22 2005-07-27 Genetic Legacy, LLC Stockage de l'information génétique
EP1563091A2 (fr) * 2002-10-04 2005-08-17 Whatman, Inc. Methodes et matieres pour une utilisation de composes chimiques, en tant qu'outils de stockage d'acide nucleique sur un support de systemes de purification d'acide nucleique
US6958392B2 (en) 1998-10-09 2005-10-25 Whatman, Inc. Methods for the isolation of nucleic acids and for quantitative DNA extraction and detection for leukocyte evaluation in blood products
US6972329B2 (en) 2001-11-15 2005-12-06 Whatman, Inc. Materials and methods for releasing genetic material
US7122304B2 (en) 1997-05-12 2006-10-17 Whatman, Inc. Methods for the storage and synthesis of nucleic acids using a solid support
US7498133B2 (en) 1999-04-14 2009-03-03 Whatman, Inc. FTA-coated media for use as a molecular diagnostic tool
US7638099B2 (en) 2004-04-09 2009-12-29 Vivebio, Llc Devices and methods for collection, storage and transportation of biological specimens
US7790865B1 (en) 1999-02-02 2010-09-07 Qiagen North American Holdings, Inc Eluting reagents, methods and kits for isolating DNA
WO2011080160A1 (fr) 2009-12-29 2011-07-07 Whatman Inc Améliorations de l'élution d'acide nucléique
WO2013104025A1 (fr) * 2012-01-11 2013-07-18 Adelaide Research & Innovation Pty Ltd Stabilisation et l'analyse d'acides gras dans un échantillon biologique stocké sur support solide
WO2014001940A1 (fr) 2012-06-26 2014-01-03 Copan Italia S.P.A. Dispositif de prélèvement, de transfert et/ou de conservation d'échantillons de substance biologique
WO2014083093A1 (fr) 2012-11-30 2014-06-05 Ge Healthcare Uk Limited Dispositif de stockage d'échantillon à communication radiofréquence
WO2015019205A1 (fr) 2013-08-07 2015-02-12 Copan Italia S.P.A. Support pour conserver un échantillon de matière biologique, et son procédé de production
WO2015090879A1 (fr) * 2013-12-18 2015-06-25 Ge Healthcare Uk Limited Stockage de données d'oligonucléotide sur supports solides
US9260711B2 (en) 2012-09-13 2016-02-16 Ge Healthcare Uk Limited Solid matrix for one step nucleic acid amplification
WO2017133738A1 (fr) * 2016-02-04 2017-08-10 Leibniz-Institut Für Pflanzenbiochemie (Ipb) Procédé, substrat et kit pour l'assemblage de type « 1 tube-1 étape » de molécules d'adn
CN111556788A (zh) * 2017-12-01 2020-08-18 意大利科潘恩集团公司 用于保存生物样品的支持物及相关生产方法
US10864518B2 (en) 2015-11-03 2020-12-15 Copan Italia S.P.A. Device for collecting, transferring, and storing samples of a biological and/or chemical material
US11315023B2 (en) 2018-04-13 2022-04-26 The Hong Kong Polytechnic University Data storage using peptides

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3025684A (en) * 1983-07-05 1985-01-10 Molecular Diagnostics, Inc. Binding nucleic acid on a support
EP0221308A1 (fr) * 1985-09-30 1987-05-13 Miles Inc. Immobilisation d'acides nucléiques sur les support du nylon dérivé
EP0261955A2 (fr) * 1986-09-26 1988-03-30 E.I. Du Pont De Nemours And Company Procédé pour l'immobilisation d'ADN

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3025684A (en) * 1983-07-05 1985-01-10 Molecular Diagnostics, Inc. Binding nucleic acid on a support
EP0221308A1 (fr) * 1985-09-30 1987-05-13 Miles Inc. Immobilisation d'acides nucléiques sur les support du nylon dérivé
EP0261955A2 (fr) * 1986-09-26 1988-03-30 E.I. Du Pont De Nemours And Company Procédé pour l'immobilisation d'ADN

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627226B2 (en) 1988-10-05 2003-09-30 Whatman, Inc. Dry solid medium for storage and analysis of genetic material
US6294203B1 (en) 1988-10-05 2001-09-25 Whatman Plc Dry solid medium for storage and analysis of genetic material
US6447804B1 (en) 1988-10-05 2002-09-10 Whatman, Plc Dry solid medium for storage and analysis of genetic material
US5985327A (en) * 1988-10-05 1999-11-16 Flinders Technologies Pty. Ltd. Solid medium and method for DNA storage
US6322983B1 (en) 1988-10-05 2001-11-27 Whatman Plc Solid medium and methods for processing a sample of genetic material
US5976572A (en) * 1991-05-29 1999-11-02 Flinders Technologies Pty. Ltd. Dry solid medium for storage and analysis of genetic material
US5756126A (en) * 1991-05-29 1998-05-26 Flinders Technologies Pty. Ltd. Dry solid medium for storage and analysis of genetic material
US5807527A (en) * 1991-05-29 1998-09-15 Flinders Technologies Pty. Ltd. Solid medium and method for DNA storage
EP0784796A1 (fr) * 1994-10-07 1997-07-23 Flinders Technologies Pty. Ltd. Appareil et procede de stockage, purification ou mise en reaction et traitement d'un biopolymere
EP0784796A4 (fr) * 1994-10-07 1998-11-11 Flinders Technologies Pty Ltd Appareil et procede de stockage, purification ou mise en reaction et traitement d'un biopolymere
AU691114B2 (en) * 1995-06-07 1998-05-07 Whatman Plc Dry solid medium for storage and analysis of genetic material
EP1484111A1 (fr) * 1995-06-07 2004-12-08 Whatman PLC Milieu solide et sec pour le stockage et l'analyse d'un matériel génétique
WO1996039813A1 (fr) * 1995-06-07 1996-12-19 Flinders Technologies Pty. Ltd. Support solide sec pour le stockage et l'analyse d'un materiau genetique
US5972386A (en) * 1995-12-19 1999-10-26 Flinders Technologies Pty, Ltd. Dry solid medium for storage and analysis of genetic material
WO1997042344A1 (fr) * 1996-05-03 1997-11-13 Institut Für Medizinische Molekulardiagnostik Gbrmbh Procede pour l'analyse genetique du sang et moyen pour sa mise en oeuvre
FR2755440A1 (fr) * 1996-11-07 1998-05-07 Tuffet Sophie Procede de conservation de longue duree de molecules d'adn et conditionnement pour sa mise en oeuvre
US7122304B2 (en) 1997-05-12 2006-10-17 Whatman, Inc. Methods for the storage and synthesis of nucleic acids using a solid support
JP2004500001A (ja) * 1998-02-02 2004-01-08 ジエントラ・システムズ・インコーポレーテツド Ｄｎａを単離するための溶解マトリックスを使用するための組成物および方法
WO1999038962A3 (fr) * 1998-02-02 1999-10-07 Gentra Systems Inc Compositions et procedes d'utilisation d'une matrice lytique pour isoler un adn
WO1999038962A2 (fr) * 1998-02-02 1999-08-05 Gentra Systems, Inc. Compositions et procedes d'utilisation d'une matrice lytique pour isoler un adn
WO1999057264A1 (fr) * 1998-05-06 1999-11-11 Sophie Tuffet Procede de conservation de longue duree de molecules d'adn et conditionnement pour sa mise en oeuvre
US6958392B2 (en) 1998-10-09 2005-10-25 Whatman, Inc. Methods for the isolation of nucleic acids and for quantitative DNA extraction and detection for leukocyte evaluation in blood products
US7790865B1 (en) 1999-02-02 2010-09-07 Qiagen North American Holdings, Inc Eluting reagents, methods and kits for isolating DNA
EP1173623A1 (fr) * 1999-03-11 2002-01-23 Whatman, Inc. Milieu solide et procede pour le stockage et la purification rapide d'acide nucleique
EP1173623A4 (fr) * 1999-03-11 2004-10-20 Whatman Inc Milieu solide et procede pour le stockage et la purification rapide d'acide nucleique
EP1177420A1 (fr) * 1999-04-14 2002-02-06 Whatman, Inc. Support revetu de fta (matiere de filtre cellulosique) utile comme outil diagnostique moleculaire
EP1177420A4 (fr) * 1999-04-14 2004-08-04 Whatman Inc Support revetu de fta (matiere de filtre cellulosique) utile comme outil diagnostique moleculaire
US7498133B2 (en) 1999-04-14 2009-03-03 Whatman, Inc. FTA-coated media for use as a molecular diagnostic tool
DE19957861A1 (de) * 1999-12-01 2001-06-13 Agrobiogen Gmbh Probenbehälter zur Lagerung und Identifizierung von DNA/RNA-haltigem Material
WO2002072870A3 (fr) * 2001-03-13 2004-04-01 Whatman Inc Milieu solide et sec pour le stockage et l'analyse d'un materiel genetique
US6972329B2 (en) 2001-11-15 2005-12-06 Whatman, Inc. Materials and methods for releasing genetic material
EP1563091A2 (fr) * 2002-10-04 2005-08-17 Whatman, Inc. Methodes et matieres pour une utilisation de composes chimiques, en tant qu'outils de stockage d'acide nucleique sur un support de systemes de purification d'acide nucleique
EP1563091A4 (fr) * 2002-10-04 2006-08-16 Whatman Inc Methodes et matieres pour une utilisation de composes chimiques, en tant qu'outils de stockage d'acide nucleique sur un support de systemes de purification d'acide nucleique
EP1557475A1 (fr) * 2004-01-22 2005-07-27 Genetic Legacy, LLC Stockage de l'information génétique
US9359649B2 (en) 2004-04-09 2016-06-07 Vivebio, Llc Methods for collection, storage and transportation of biological specimens
US7638099B2 (en) 2004-04-09 2009-12-29 Vivebio, Llc Devices and methods for collection, storage and transportation of biological specimens
US8685748B2 (en) 2004-04-09 2014-04-01 Vivebio, Llc Devices and methods for collection, storage and transportation of biological specimens
WO2011080160A1 (fr) 2009-12-29 2011-07-07 Whatman Inc Améliorations de l'élution d'acide nucléique
WO2013104025A1 (fr) * 2012-01-11 2013-07-18 Adelaide Research & Innovation Pty Ltd Stabilisation et l'analyse d'acides gras dans un échantillon biologique stocké sur support solide
US9645132B2 (en) 2012-01-11 2017-05-09 Adelaide Research & Innovation Pty Ltd Stabilising and analysing fatty acids in a biological sample stored on solid media
WO2014001940A1 (fr) 2012-06-26 2014-01-03 Copan Italia S.P.A. Dispositif de prélèvement, de transfert et/ou de conservation d'échantillons de substance biologique
US10220390B2 (en) 2012-06-26 2019-03-05 Copan Italia S.P.A. Device for collecting and transferring samples of biological material
US11052397B2 (en) 2012-06-26 2021-07-06 Copan Italia S.P.A. Device and a method for collecting and transferring samples of biological material
US9260711B2 (en) 2012-09-13 2016-02-16 Ge Healthcare Uk Limited Solid matrix for one step nucleic acid amplification
US11175287B2 (en) 2012-11-30 2021-11-16 Qiagen Healthcare Biotechnologies Systems Gmbh Biometric device and means for electronic storage and retrieval of biometric data
WO2014083093A1 (fr) 2012-11-30 2014-06-05 Ge Healthcare Uk Limited Dispositif de stockage d'échantillon à communication radiofréquence
US9618428B2 (en) 2012-11-30 2017-04-11 Ge Healthcare Uk Limited Biometric device and means for electronic storage and retrieval of biometric data
US10646872B2 (en) 2013-08-07 2020-05-12 Copan Italia S.P.A. Support for conserving a sample of biological material and a method for production thereof
WO2015019205A1 (fr) 2013-08-07 2015-02-12 Copan Italia S.P.A. Support pour conserver un échantillon de matière biologique, et son procédé de production
WO2015090879A1 (fr) * 2013-12-18 2015-06-25 Ge Healthcare Uk Limited Stockage de données d'oligonucléotide sur supports solides
US11931713B2 (en) 2013-12-18 2024-03-19 Global Life Sciences Solutions Operations UK Ltd Oligonucleotide data storage on solid supports
US10864518B2 (en) 2015-11-03 2020-12-15 Copan Italia S.P.A. Device for collecting, transferring, and storing samples of a biological and/or chemical material
EP3834941A2 (fr) 2015-11-03 2021-06-16 Copan Italia S.P.A. Dispositif de collecte, de transfert et de stockage d'échantillons d'un matériau biologique et/ou chimique
WO2017133738A1 (fr) * 2016-02-04 2017-08-10 Leibniz-Institut Für Pflanzenbiochemie (Ipb) Procédé, substrat et kit pour l'assemblage de type « 1 tube-1 étape » de molécules d'adn
US11254929B2 (en) 2016-02-04 2022-02-22 Leibniz-Institut Fuer Pflanzenbiochemie (Ipb) Method, substrate and kit for one-pot one-step assembly of DNA molecules
CN111556788A (zh) * 2017-12-01 2020-08-18 意大利科潘恩集团公司 用于保存生物样品的支持物及相关生产方法
US11315023B2 (en) 2018-04-13 2022-04-26 The Hong Kong Polytechnic University Data storage using peptides

Also Published As

Publication number Publication date
CA2000192A1 (fr) 1990-04-05

Similar Documents

Publication Publication Date Title
US5496562A (en) Solid medium and method for DNA storage
US5807527A (en) Solid medium and method for DNA storage
US6322983B1 (en) Solid medium and methods for processing a sample of genetic material
WO1990003959A1 (fr) Milieu solide et procede de stockage d'adn
US5756126A (en) Dry solid medium for storage and analysis of genetic material
EP1484111B1 (fr) Milieu solide et sec pour le stockage et l'analyse d'un matériel génétique
US5972386A (en) Dry solid medium for storage and analysis of genetic material
US6627226B2 (en) Dry solid medium for storage and analysis of genetic material
JP4585123B2 (ja) 生体材料からのｄｎａの単離方法
JP3943601B2 (ja) アルカリプロテアーゼを用いる核酸の単離方法
EP2521780B1 (fr) Procédé pour isoler des acides nucléiques, et kit à cet effet
US6447804B1 (en) Dry solid medium for storage and analysis of genetic material
US20040014068A1 (en) Solid medium and method for DNA storage
EP0713528B1 (fr) Extraction in situ d'adn microbien
JP2006517225A (ja) 核酸抽出のための生物学的試料の化学処理および該処理用のキット
US20040126796A1 (en) Extraction of DNA from biological samples
WO1996011406A1 (fr) Appareil et procede de stockage, purification ou mise en reaction et traitement d'un biopolymere
EP1109899B1 (fr) Produit et methode de separation d'un echantillon contenant des sources multiples de materiel genetique utilisant un milieu solide
US20050282180A1 (en) Solid medium and method for DNA storage
JP4831725B2 (ja) 簡易的核酸抽出法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE